Peptide Price Finder

Home · Research · Longevity & bioregulators

Vilon research

What published studies found for Vilon: 12 papers, 7 in humans, with sample sizes and key results.

C
Mostly animal studies
Why: Human reports are small, mostly uncontrolled Russian studies without numbers; the evidence comes mainly from rodent studies, with mixed tumor effects.

Vilon (Lys-Glu dipeptide) has been studied almost exclusively by Russian groups, mainly in rodents and cell cultures. The human data are small, mostly uncontrolled Russian-language reports (diabetes, cancer, goitre, appendicitis, periodontitis) that lack controls or statistics, so no benefit is established; animal findings are mixed, including more breast cancer in one transgenic mouse study.

✓ 3 positive✗ 1 negative~ 1 mixed? 7 inconclusive

No human adverse-event data in the candidates; one mouse study found Vilon accelerated breast cancer development.

US compounding: Not compoundable. Not an FDA-approved drug and not nominated for FDA's 503A bulks list, so US pharmacies can't legally compound it. Status for every peptide.

Browse and filter these papersVilon prices and vendors

Human studies

? Inconclusivehuman RCTAdv Gerontol · 2006

[Effect of thymomimetic vilon on blood coagulation system and fibrinolisis in diabetes mellitus type 1 patients of different age].

Number of patients not stated in abstractClinical study; Vilon (Lys-Glu) added to treatment (design details not stated)

Russian report in type 1 diabetes patients: adding Vilon reportedly reduced or abolished signs of chronic intravascular coagulation (DIC), less so in elderly patients with severe disease; patient numbers and effect sizes are not given in the abstract.

Studied
Patients with type 1 diabetes mellitus of different ages, in destabilization stage
Main outcome
Blood coagulation, fibrinolysis, DIC syndrome signs
Authors' conclusion
Administration of thymomimetic Vilon significantly reduces or even totally diminishes DIC syndrome in type 1 diabetes patients; the effect is less pronounced in elderly patients with severe disease.
Limitations
Abstract gives no patient numbers, control group or effect sizes.
PubMed 17152731
? Inconclusivehuman trialДальневосточный медицинский журнал · 2007Russian-language

Опыт клинического применения тимомиметика вилона в лечении диффузного токсического зоба

n = 37 humansClinical observation of Vilon added to treatment; controls not described in the abstract8-10 days of injections

37 patients with Graves-type diffuse toxic goitre given Vilon injections reached clinical euthyroidism faster and had normalised T3/T4, per the authors; the abstract does not describe a control group (Russian journal).

Studied
Patients with diffuse toxic goitre
Main outcome
Time to clinical euthyroidism; thyroid hormone (T3, T4) levels
Sample
37 patients with diffuse toxic goitre
Authors' conclusion
Vilon given over 8-10 days led to faster clinical euthyroidism and normalisation of T3 and T4 levels.
Limitations
Control group and effect sizes not given in the abstract; Russian regional journal.
CyberLeninka (Russian)
? Inconclusivehuman trialДальневосточный медицинский журнал · 2008Russian-language

Применение вилона в лечении онкопатологии у пожилых больных с неоперабельными формами рака

n = 30 humansClinical-immunological observation; radiotherapy plus Vilon, no control group statedTwo courses over 1 month; survival followed 2 years

30 elderly patients with inoperable stage III-IV cancer received radiotherapy plus Vilon; tumours shrank 30-80% and 2-year survival was 90%, but there was no control group (Russian journal, uncontrolled).

Key resultTumour size fell 30-80%; 2-year survival 90%; lymphocytes, CD4+ cells fell and CD16+ cells rose by 1 month
Studied
Elderly patients with inoperable stage III-IV cancers of various sites
Main outcome
Tumour size, tolerance of radiotherapy, survival, immune markers
Sample
30 patients with inoperable stage III-IV cancers
Authors' conclusion
Authors report positive clinical dynamics and good tolerance of radiotherapy and call Vilon promising for practical oncology.
Limitations
No control group; Vilon cannot be separated from radiotherapy; Russian regional journal.
CyberLeninka (Russian)
? Inconclusivehuman trialAdv Gerontol · 2007

[Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus].

Number of patients not stated in abstractVilon added to complex therapy (design details not stated)

In elderly type 1 diabetes patients, adding Vilon reportedly raised natural anticoagulants, stimulated fibrinolysis, normalized some immune markers and often lowered insulin requirement; no numbers reported.

Studied
Elderly patients with type 1 diabetes mellitus
Main outcome
Immune status and coagulation hemostasis
Authors' conclusion
Vilon added to complex therapy optimized coagulation hemostasis (more antithrombin III and protein C, stimulated fibrinolysis), reduced insulin dose in most cases and normalized some immune markers.
Limitations
Abstract gives no patient numbers, control group or effect sizes.
PubMed 18306698
? Inconclusivehuman trialAdv Gerontol · 2005

[Application of peptide bioregulator in complex treatment of elderly cancer patients].

Number of patients not stated in abstractPreliminary experience with Vilon added to complex radical treatment

Preliminary controlled report in elderly stage III colorectal cancer patients suggesting Vilon added to standard treatment improved 2-year survival and reduced complications; no figures given.

Studied
Elderly patients with stage III rectal and colon cancer
Main outcome
2-year survival, complications, recurrence, quality of life
Authors' conclusion
Preliminary results suggest Vilon may increase 2-year survival and help prevent postoperative complications, recurrences and dissemination, and improve quality of life.
Limitations
Preliminary results; no numbers, no stated control group in abstract.
PubMed 16075684
? Inconclusivehuman trialМедицинская иммунология · 2008Russian-language

Сравнительное действие тималина, эпиталамина и вилона на состояние иммунитета у больных с осложненным течением острого аппендицита

Patient numbers not stated in the abstractComparative clinical study of three peptide preparations added to conventional treatment5 or 10 days of injections

In patients with complicated appendicitis, adding Vilon (5 or 10 days), Thymalin or Epitalamin to standard care was reported to stimulate immunity, aid primary wound healing and shorten treatment by about 5-6 days; sample size not given in the abstract.

Key resultTreatment shortened by a mean of 5-6 days; Vilon needed half as many injections as Thymalin or Epitalamin
Studied
Patients with complicated acute appendicitis
Compared with
Conventional treatment; Thymalin and Epitalamin as comparators
Main outcome
Immune parameters, wound healing, length of treatment
Authors' conclusion
The authors report immunostimulation, primary wound healing and shorter treatment with the peptides, with Vilon needing about half as many injections.
Limitations
Abstract gives no sample size or statistics; Vilon cannot be separated from comparators on the evidence stated.
CyberLeninka (Russian)
? Inconclusivehuman trialДальневосточный медицинский журнал · 2014Russian-language

Лечение хронического генерализованного пародонтита с применением Вилона у больных пожилого и старческого возраста

Patient numbers not stated in the text availableComparison of standard treatment vs standard treatment plus Vilon3 months follow-up

Elderly patients with chronic generalized periodontitis given Vilon plus standard treatment were compared with standard treatment alone; after 3 months standard-only patients had relapsed to baseline while about half of the Vilon group showed remission (small unclear design, Russian regional journal).

Key resultRemission in 50 % of Vilon-treated elderly patients; standard-treatment groups returned to pre-treatment values by 3 months
Studied
Elderly and senile patients with chronic generalized periodontitis
Compared with
Standard treatment
Main outcome
Clinical picture and periodontal indices
Authors' conclusion
Adding Vilon to complex treatment is said to improve clinical results in elderly periodontitis patients.
Limitations
Sample size, randomization and statistics are not given in the abstract.
CyberLeninka (Russian)

Animal & lab studies

✗ NegativeanimalInt J Cancer · 2002

Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice.

Number of mice not stated in abstractSubcutaneous saline, Epitalon or Vilon (1 ug/mouse, 5 consecutive days every month) from age 2 months

In HER-2/neu transgenic mice, Vilon increased mammary cancer incidence, shortened tumor latency and increased tumor number vs saline (whereas Epitalon reduced tumors).

Key resultVilon increased mammary cancer incidence, shortened mean tumor latent period and increased cumulative number of tumors (all p<0.05) vs control
Studied
Female FVB/N HER-2/neu transgenic mice
Compared with
Saline
Main outcome
Mammary tumor incidence, latency, number and size
Authors' conclusion
Epitalon inhibited spontaneous mammary tumor development; Vilon produced significant negative effects on tumor outcomes compared to control.
Limitations
Mouse study; paper focuses on Epitalon.
PubMed 12209581DOI
✓ PositiveanimalBull Exp Biol Med · 2000

Effect of vilon on biological age and lifespan in mice.

Number of mice not stated in abstractSubcutaneous Vilon (Lys-Glu) from the 6th month of lifeLong-term (lifespan)

Long-term Vilon in female CBA mice increased physical activity and endurance, prolonged lifespan and prevented spontaneous tumors, with no adverse effects on development noted.

Studied
Female CBA mice
Main outcome
Physical activity, endurance, lifespan, spontaneous neoplasms
Authors' conclusion
Vilon increased physical activity and endurance, prolonged lifespan and prevented spontaneous neoplasms, with no unfavourable effects on development; authors propose it for geroprotection.
Limitations
Mouse study; no numbers in abstract.
PubMed 11140587DOI
✓ PositiveanimalBull Exp Biol Med · 2001

Inhibitory effect of peptide vilon on the development of induced rat urinary bladder tumors in rats.

Number of rats not stated in abstractVilon (Lys-Glu) vs controls during carcinogen-induced bladder carcinogenesis

In rats given a bladder carcinogen, tumors developed in 56% of Vilon-treated vs 75.5% of control animals.

Key resultTumors developed in 56% of vilon-treated animals vs 75.5% of controls; preneoplastic and early neoplastic changes decreased 2-fold
Studied
Rats with urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)nitrosamine
Compared with
Controls
Main outcome
Tumor incidence and preneoplastic changes
Authors' conclusion
Vilon significantly inhibited induced bladder carcinogenesis in rats.
Limitations
Rat study; group sizes not stated in abstract.
PubMed 11586406DOI
~ MixedanimalAdv Gerontol · 2003

[Combined effect of vilon and cyclophosphane on tumor transplants and lymphoid tissue explants in mice and rats of various age].

Humans and animalsVilon (1 mg/kg), cyclophosphan (100 mg/kg) alone and together; organotypic spleen culture

In mice with transplanted lung carcinoma, Vilon alone increased survival, but giving it together with cyclophosphamide decreased survival.

Studied
Mice with transplanted Lewis lung carcinoma; spleen explant cultures from 1-day-old and 2-year-old rats
Main outcome
Survival of tumor-bearing mice; apoptosis and explant development in culture
Authors' conclusion
Vilon alone increased survival, while simultaneous vilon and cyclophosphan decreased survival; the authors suggest they should not be used synchronously.
Limitations
Animal and tissue culture study; no numbers in abstract.
PubMed 14743610
✓ PositiveanimalBull Exp Biol Med · 2015

Comparison of treatment options for experimental endometriosis in rats.

AnimalsAnimal experiment comparing surgery, Vilon, and both

In rats with experimental endometriosis, surgery combined with intraperitoneal Vilon gave the best reproductive-function outcomes of the options compared (the developer's group; abstract gives no numbers).

Studied
Rats with experimental endometriosis
Compared with
Surgery alone, Vilon alone
Main outcome
Reproductive function
Authors' conclusion
Surgery combined with intraperitoneal Vilon is described as a promising option for treating endometriosis.
Limitations
Animal study; no quantitative results in the abstract.
PubMed 25778659DOI

Verdicts are judged on each paper's own main outcome; grades run from A (strong human evidence) to D (little or none). Details are read from the abstracts, and figures are reproduced only from openly licensed full texts. Not medical advice.